Gentian Diagnostics AS (OSL:GENT) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 04, 2026)


OSL:GENT Gentian Diagnostics AS OSL:GENT
72 GF Score
Price kr37.00
GF Value kr61.81
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Gentian Diagnostics AS Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Gentian Diagnostics AS's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

OSL:GENT vs ABT, SYK, MDT: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Devices subindustry, Gentian Diagnostics AS's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gentian Diagnostics AS Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Gentian Diagnostics AS's Margin of Safety % (DCF Earnings Based) falls into.


OSL:GENT
72GF Score
Gentian Diagnostics AS OSL:GENT
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?

Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued. The current stock price of kr37.00 is trading 40.1% below its estimated GF Value™ of kr61.81. GuruFocus considers Gentian Diagnostics AS to be Possible Value Trap.

Key valuation signals for OSL:GENT:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: kr61.81 vs. price of kr37.00 (40.1% below fair value)
  • GF Score™: 72/100 with 1 warning sign

No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gentian Diagnostics AS Business Description

Other Exchanges GENTOo:Sweden6FK:Germany
Address Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
72GF Score

Get the complete analysis for OSL:GENT

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr37.00
Price
kr61.81
GF Value